相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling
Xiaoyang Ling et al.
CANCER RESEARCH (2007)
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
Michele Milella et al.
BLOOD (2007)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
The ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors
Els Lierman et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
G. J. Roboz et al.
LEUKEMIA (2006)
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation
W Zhang et al.
LEUKEMIA (2005)
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
M Rahmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type
WN Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia
MR Ricciardi et al.
LEUKEMIA (2005)
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
M Levis et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
K Bagrintseva et al.
BLOOD (2004)
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
H Minderman et al.
CLINICAL CANCER RESEARCH (2004)
Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations
MP Oyarzo et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses
L Zhao et al.
CLINICAL CANCER RESEARCH (2004)
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia
M Konopleva et al.
CANCER RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
Design and discovery of small molecules targeting Raf-1 kinase
TB Lowinger et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
XM Deng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Rsk1 mediates a MEK-MAP kinase cell survival signal
A Shimamura et al.
CURRENT BIOLOGY (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
分享论文
